Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| IMTX | PRESS-RELEASE | bullish | 6/10 | Immatics presented extended Phase 1 data for its TCR bispecific IMA401 at ASCO 2026, showing a 29% confirmed ORR and 64% | May 31, 2026 |
| RVMD | PRESS-RELEASE | bullish | 8/10 | Revolution Medicines reported overwhelmingly positive Phase 3 data for daraxonrasib in metastatic pancreatic cancer, sho | May 31, 2026 |
| REPL | PRESS-RELEASE | bullish | 6/10 | Replimune presented final Phase 1 data for RP2 (alone and with nivolumab) at ASCO 2026, showing durable responses in hea | May 31, 2026 |
| IMCR | PRESS-RELEASE | bullish | 6/10 | Immunocore presented updated Phase 1 data for brenetafusp in heavily pretreated advanced melanoma at ASCO 2026, showing | May 31, 2026 |
| EIKN | PRESS-RELEASE | neutral | 5/10 | Eikon Therapeutics presented updated Phase 2 data for EIK1001 (TLR7/8 agonist) in first-line NSCLC at ASCO 2026, showing | May 30, 2026 |
| BNTX | PRESS-RELEASE | bullish | 7/10 | BioNTech and BMS announced positive interim Phase 2 data for pumitamig (PD-L1xVEGF bispecific) plus chemotherapy in firs | May 30, 2026 |
| MLYS | PRESS-RELEASE | bullish | 7/10 | Mineralys Therapeutics presented positive post-hoc data from the Phase 3 Launch-HTN trial at ESH 2026, showing lorundros | May 30, 2026 |
| IMTX | PRESS-RELEASE | bullish | 7/10 | Immatics reported updated Phase 1 data for IMA203CD8 PRAME cell therapy at ASCO 2026, showing 63% ORR (50% cORR) in heav | May 30, 2026 |
| REPL | PRESS-RELEASE | bullish | 8/10 | Replimune presented 3-year landmark overall survival data from the IGNYTE trial of RP1 plus nivolumab in anti-PD-1-faile | May 30, 2026 |
| COGT | PRESS-RELEASE | bullish | 8/10 | Cogent Biosciences reported highly positive Phase 3 PEAK trial results for bezuclastinib in combination with sunitinib i | May 30, 2026 |
| SION | CLUSTER | neutral | 2/10 | Two directors sold a combined $9K in SION stock on May 27, 2026, a trivial amount relative to the $1.9B market cap. The | May 29, 2026 |
| SION | 144 | bearish | 6/10 | OrbiMed Advisors LLC filed a Form 144 on May 29, 2026, signaling intent to sell 1,082,480 shares of Sionna Therapeutics | May 29, 2026 |
| EQ | CLUSTER | neutral | 4/10 | Two Equillium insiders (COO and Principal Accounting Officer) sold a combined $342K in open-market sales on May 28, 2026 | May 29, 2026 |
| CORT | CLUSTER | neutral | 3/10 | Two Corcept Therapeutics insiders sold a total of ~$3.9M in open-market shares on May 27, 2026, while a director gifted | May 29, 2026 |
| NBIX | CLUSTER | neutral | 3/10 | Two Neurocrine executives sold shares totaling $2.32M in the week following the close of the $2.9B Soleno acquisition. T | May 29, 2026 |
| EXEL | CLUSTER | neutral | 3/10 | Two EVPs at Exelixis sold a combined $3.79M in open-market sales over a week, while seven directors received non-cash st | May 29, 2026 |
| GEVO | CLUSTER | bearish | 5/10 | Three top executives at Gevo, CEO, CFO, and President/COO, sold a combined $344K in open-market shares on May 27, 2026, | May 29, 2026 |
| JAGX | DEFA14A | neutral | 4/10 | Jaguar Health filed a DEFA14A supplement to its definitive proxy statement, clarifying terms of Proposal 3 (equity line | May 29, 2026 |
| ESPR | PREM14A | bullish | 6/10 | Esperion Therapeutics has filed a preliminary proxy statement (PREM14A) for its acquisition by an affiliate of ArchiMed | May 29, 2026 |
| CELU | PRESS-RELEASE | bearish | 6/10 | Celularity disclosed a Nasdaq late filing notice for its overdue Q1 2026 10-Q. The delayed filing triggers a 60-day cure | May 29, 2026 |
| RDY | 20-F | neutral | 2/10 | Dr. Reddy's filed its annual Form 20-F for the fiscal year ended March 31, 2026, a routine annual report with no new mat | May 29, 2026 |
| ATNM | 8-K | bearish | 7/10 | Actinium Pharmaceuticals received a delisting notice from NYSE American for failing to meet the $4.0M minimum stockholde | May 29, 2026 |
| CRDF | 8-K | bearish | 8/10 | Cardiff Oncology disclosed that its licensor, Nerviano Medical Sciences (NMS), has terminated the key license agreement | May 29, 2026 |
| TNYA | 8-K | neutral | 3/10 | Tenaya Therapeutics held its 2026 annual meeting on May 27, 2026, where shareholders approved an amended and restated 20 | May 29, 2026 |
| TPST | 8-K | neutral | 2/10 | Director Ms. Simantov resigned from the board of Tempest Therapeutics effective May 23, 2026, with no disagreement discl | May 29, 2026 |
| SCNX | 8-K | neutral | 4/10 | Scienture Holdings CFO Eric Sherb resigned effective May 26, 2026 for personal reasons, with no dispute or disagreement. | May 29, 2026 |
| HURA | 8-K | neutral | 4/10 | TuHURA Biosciences drew $1.7M from its $50M revolving credit facility with Parkview Holdings One LLC, the first draw und | May 29, 2026 |
| CLDWW | 8-K | neutral | 4/10 | Calidi Biotherapeutics issued an amended and restated warrant to purchase up to 17,391,304 shares of common stock at $0. | May 29, 2026 |
| SVA | 6-K | bearish | 7/10 | Sinovac Biotech received a Nasdaq delist determination letter on May 22, 2026 for failing to timely file its 2025 Annual | May 29, 2026 |
| MNPR | 8-K | neutral | 4/10 | Monopar Therapeutics presented Phase 2 study results for ALXN1840 (tiomolibdate choline) in Wilson disease at the EASL I | May 29, 2026 |